Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q2 2022 call → NOWe need to determine if management explains where the company's business is going by narrating what its counterparties are themselves doing and scaling. The counterparties here would be surgeons, hospitals, or other customers. The transcript discusses active surgeon base, surgeon utilization, training programs, DTC programs, direct sales force expansion, etc. Management talks about surgeon adoption, training events, and how surgeons are using the product more over time. However, the question is whether management's forward account is substantially about the growth of specific counterparties (like surgeons or hospitals) as opposed to the company's own selling efforts. The transcript focuses on the company's own initiatives: expanding direct sales force, DTC programs, product innovations, and surgeon training. It mentions surgeon base growth and utilization, but that is more about the company's market penetration and selling efforts. The counterparties are surgeons, but management does not narrate their own independent trajectories (like their own expansion plans) as the driver. Instead, it's about the company's efforts to train and convert them. The direction of explanation is the company's own actions. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.